Compare Johnson & Johnson (JNJ) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Open Text Corporation — how do they compare? Johnson & Johnson trades at $250.44 (market cap $598.96B), while Open Text Corporation trades at $23.23 (market cap $5.61B). The key difference: Johnson & Johnson is far larger — about 106.8× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| JNJ | OTEX | |
|---|---|---|
Market Cap | $598.96B | $5.61B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $39.69 |
52-Week Low | $164.36 | $20.01 |
Enterprise Value | $631.90B | $10.77B |
Dividend Yield | 2.15% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
OpenText (OTEX) trades at $23.33, up 0.26% with a bullish technical signal from moving averages. The company shows solid fundamentals with a P/E of 11.3, EV/EBITDA of 6.71, and consistent earnings beats in recent quarters. Recent developments include a $105 million European AI investment and board appointments, while maintaining a 4.7% dividend yield.
OTEX presents value opportunity with attractive valuation multiples and strong cash flow generation. Key risks include execution challenges in AI strategy and competitive software market pressures. Analyst consensus targets $29.75 (27.5% upside) with 42% buy ratings, though majority maintain hold stance awaiting clearer growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
